FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079798757> ?p ?o ?g. }

• W2079798757 endingPage "34" @default.
• W2079798757 startingPage "25" @default.
• W2079798757 abstract "Zoledronic acid (Zometa, Novartis Pharmaceuticals Corp, East Hanover, NJ) is a new, highly potent bisphosphonate that may provide improved management of skeletal complications in cancer patients with bone metastases. A total of 383 cancer patients with osteolytic bone lesions was evaluated in two phase I studies and one phase II study of zoledronic acid. The phase I studies used two dosing regimens, either a 5-minute monthly intravenous infusion of 0.1 to 8 mg administered for 3 or more months or a single 30 to 60 second intravenous bolus of 1 to 16 mg. Zoledronic acid was well tolerated in the two phase I studies and a maximum tolerated dose was not reached in either study. A dose-dependent decrease in urinary markers of bone resorption was observed with the monthly 5-minute infusion. A single intravenous bolus of doses ranging from 2 to 16 mg zoledronic acid suppressed biochemical markers of bone resorption for up to 8 weeks. The phase II study evaluated a 5-minute infusion of 0.4, 2, or 4 mg zoledronic acid and a 2-hour infusion of 90 mg pamidronate in 280 patients with bone metastases and multiple myeloma or breast cancer. Significantly fewer patients receiving the 2 and 4 mg doses of zoledronic acid or 90 mg pamidronate required radiation therapy to bone than those patients receiving a 0.4 mg dose of zoledronic acid. Only 30% to 35% of patients in the 2 and 4 mg zoledronic acid groups or in the pamidronate group experienced any skeletal related event compared with 46% in the 0.4 mg zoledronic acid group. Adverse events consistent with an acute phase reaction were observed with both bisphosphonates. No new, unexpected adverse events were observed with this novel bisphosphonate. These studies support the further evaluation of zoledronic acid in cancer patients with osteolytic metastases. Doses of 0.4 mg or less are ineffective, while rapid infusion of more than 8 mg may increase the risk of renal dysfunction. A 4 mg dose given as a brief infusion appears to offer an excellent benefit/risk ratio for further evaluation in phase III trials." @default.
• W2079798757 created "2016-06-24" @default.
• W2079798757 creator A5040835019 @default.
• W2079798757 date "2001-04-01" @default.
• W2079798757 modified "2023-10-14" @default.
• W2079798757 title "Zoledronic acid in cancer patients with bone metastases: Results of phase I and II trials" @default.
• W2079798757 cites W1532955823 @default.
• W2079798757 cites W1750202810 @default.
• W2079798757 cites W1768011742 @default.
• W2079798757 cites W1903452192 @default.
• W2079798757 cites W1906721103 @default.
• W2079798757 cites W1932993947 @default.
• W2079798757 cites W1951349736 @default.
• W2079798757 cites W1967875617 @default.
• W2079798757 cites W1970993628 @default.
• W2079798757 cites W1974568982 @default.
• W2079798757 cites W1982915376 @default.
• W2079798757 cites W2003949207 @default.
• W2079798757 cites W2026391181 @default.
• W2079798757 cites W2043471712 @default.
• W2079798757 cites W2052104719 @default.
• W2079798757 cites W2058860389 @default.
• W2079798757 cites W2063699543 @default.
• W2079798757 cites W2066845679 @default.
• W2079798757 cites W2072789990 @default.
• W2079798757 cites W2073587921 @default.
• W2079798757 cites W2074890088 @default.
• W2079798757 cites W2082333541 @default.
• W2079798757 cites W2122560580 @default.
• W2079798757 cites W2130251213 @default.
• W2079798757 cites W2163895773 @default.
• W2079798757 cites W2316096113 @default.
• W2079798757 cites W2325302070 @default.
• W2079798757 cites W2327350066 @default.
• W2079798757 cites W2336517627 @default.
• W2079798757 cites W2616256733 @default.
• W2079798757 cites W574498656 @default.
• W2079798757 cites W1972200301 @default.
• W2079798757 doi "https://doi.org/10.1016/s0093-7754(01)90262-3" @default.
• W2079798757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11346862" @default.
• W2079798757 hasPublicationYear "2001" @default.
• W2079798757 type Work @default.
• W2079798757 sameAs 2079798757 @default.
• W2079798757 citedByCount "45" @default.
• W2079798757 countsByYear W20797987572012 @default.
• W2079798757 countsByYear W20797987572013 @default.
• W2079798757 countsByYear W20797987572016 @default.
• W2079798757 countsByYear W20797987572020 @default.
• W2079798757 countsByYear W20797987572021 @default.
• W2079798757 countsByYear W20797987572022 @default.
• W2079798757 countsByYear W20797987572023 @default.
• W2079798757 crossrefType "journal-article" @default.
• W2079798757 hasAuthorship W2079798757A5040835019 @default.
• W2079798757 hasConcept C121608353 @default.
• W2079798757 hasConcept C126322002 @default.
• W2079798757 hasConcept C126894567 @default.
• W2079798757 hasConcept C141071460 @default.
• W2079798757 hasConcept C2776169692 @default.
• W2079798757 hasConcept C2776326535 @default.
• W2079798757 hasConcept C2776541429 @default.
• W2079798757 hasConcept C2777251235 @default.
• W2079798757 hasConcept C43376680 @default.
• W2079798757 hasConcept C530470458 @default.
• W2079798757 hasConcept C673006 @default.
• W2079798757 hasConcept C71924100 @default.
• W2079798757 hasConceptScore W2079798757C121608353 @default.
• W2079798757 hasConceptScore W2079798757C126322002 @default.
• W2079798757 hasConceptScore W2079798757C126894567 @default.
• W2079798757 hasConceptScore W2079798757C141071460 @default.
• W2079798757 hasConceptScore W2079798757C2776169692 @default.
• W2079798757 hasConceptScore W2079798757C2776326535 @default.
• W2079798757 hasConceptScore W2079798757C2776541429 @default.
• W2079798757 hasConceptScore W2079798757C2777251235 @default.
• W2079798757 hasConceptScore W2079798757C43376680 @default.
• W2079798757 hasConceptScore W2079798757C530470458 @default.
• W2079798757 hasConceptScore W2079798757C673006 @default.
• W2079798757 hasConceptScore W2079798757C71924100 @default.
• W2079798757 hasLocation W20797987571 @default.
• W2079798757 hasLocation W20797987572 @default.
• W2079798757 hasOpenAccess W2079798757 @default.
• W2079798757 hasPrimaryLocation W20797987571 @default.
• W2079798757 hasRelatedWork W1769645042 @default.
• W2079798757 hasRelatedWork W1978247877 @default.
• W2079798757 hasRelatedWork W1984016106 @default.
• W2079798757 hasRelatedWork W2003038734 @default.
• W2079798757 hasRelatedWork W2016633849 @default.
• W2079798757 hasRelatedWork W2125976746 @default.
• W2079798757 hasRelatedWork W2153137996 @default.
• W2079798757 hasRelatedWork W2406596534 @default.
• W2079798757 hasRelatedWork W1862827695 @default.
• W2079798757 hasRelatedWork W1964002974 @default.
• W2079798757 hasVolume "28" @default.
• W2079798757 isParatext "false" @default.
• W2079798757 isRetracted "false" @default.
• W2079798757 magId "2079798757" @default.
• W2079798757 workType "article" @default.